PASG Insider Trading - Passage Bio, Inc.

발행주식수	3,207,810 shares
내부자 지분	1,614,578 shares
내부자 주주	50.33 %
전체 내부자	33

내부자 센티멘트 점수

내부자 센티멘트 점수를 통해서 내부자들이 법인 지분을 매입하는 기업들에 대해서 알아볼 수 있습니다.

이는 내부자의 누적도가 가장 높은 기업을 식별하는 정교하고 복합적인 지수를 분석하는 계량 모델의 결과 값입니다. 스코어링 모델은 이전 90일 동안 매수한 "내부자의 순 숫자", "매수한 주식의 총합", "내부자가 소유한 주식의 총합"의 조합을 사용합니다. 점수는 0에서 100 사이이며, 점수가 높을수록 피어(Peer: 동종업계 경쟁기업)에 대한 누적도가 높다는 것을 나타내며, 평균은 50입니다.

업데이트 주기: 일별

내부자의 누적도가 가장 높은 기업 목록을 확인할 수 있는 내부자들의 최다 선택(Insiders Top Picks)을 참고하십시오.

가장 높은 순위의 주식을 확인하세요

내부 경영진 센티멘트 점수

내부 경영진 센티멘트 점수를 통해서 내부 경영진들이 법인 지분을 매입하는 기업들에 대해서 알아볼 수 있습니다.

내부 거래의 정의에 따라 내부 경영진(기업 임원)도 내부자이지만, 다른 내부자(10% 주주 및 이사회 구성원)들과는 달리 내부 경영진은 매일 회사에서 근무하며, 거래 시에 자신의 자금을 사용합니다. (많은 경우에 10% 주주 및 이사회 구성원은 다른 사람의 자금을 관리하는 자금 관리자입니다.) 따라서 내부 경영진(기업 임원: Officer)의 내부 거래는 훨씬 더 중요하며 올바른 분석이 필요합니다.

내부자 센티멘트 점수와 마찬가지로 임원 감정 점수는 가장 높은 수준의 임원 축적을 가진 기업을 식별하는 정교하고 복합적인 지수 퀀트(Multi-factor quantitative) 모델의 결과입니다.

업데이트 주기: 일별

내부자의 누적도가 가장 높은 기업 목록을 확인할 수 있는 내부자들의 최다 선택(Insiders Top Picks)을 참고하십시오.

가장 높은 순위의 주식을 확인하세요

주요 내부자 지표

이 수치는 해당 기업이 다양한 내부자 지표에 따라 어떻게 순위를 매겨지는 지를 설명합니다. 백분위 순위는 이 기업이 미국 시장의 다른 기업들과 어떻게 비교되는지 보여줍니다. 순위가 높을수록 더 나은 상황에 있다는 것을 의미합니다.

예를 들어, 일반적으로 내부자의 매입은 긍정적인 지표라고 간주되어지기 때문에, 내부자의 매입(내부자의 매각, 역시도)가 적은 기업보다 내부자의 매입이 많은 기업은 순위가 높을 것입니다.

내부자의 순 매입(순위)

0 ( )

8976 out of 10916

내부자의 순 매입(Net Number of Insiders Buying)는 내부자 매수의 총 수에서 지난 90일 동안의 내부자 매도의 총 수를 뺀 값입니다. 여기에 백분위 순위가 표시됩니다(범위: 0~100%).

내부자가 매입한 플로트 비율 (순위)

0.000% ( )

5608 out of 10786

"내부자가 매입한 플로트 비율(Percent of Float Bought by Insiders)"은 내부자가 매입한 주식의 총 수에서 내부자가 매도한 주식의 총 수를 뺀 값을 전체 플로트로 나눈 값에 100을 곱한 값입니다. * ((내부자가 매입한 주식의 총 수 - 내부자가 매도한 주식의 총 수) ÷ 전체 플로트) x 100

내부자 트레이딩 차트

Passage Bio, Inc. 내부자의 매매 거래는 아래 차트에 나와 있습니다. 내부자들은 기업의 임원(내부 경영진), 이사 또는 주요 투자자입니다. 일반적으로 내부자가 중요한 비공개 정보를 기반으로 자신이 속한 기업을 거래하는 것은 불법으로 간주됩니다. 이것은 내부자가 자신의 기업 내에서 행하는 모든 거래가 불법이라는 것을 뜻은 아닙니다. 그러나 그들은 자신들의 모든 거래를 양식 4를 통해 SEC에 보고해야만 합니다.

내부자의 명단 및 이익 지표

아래 표는 공개된 내부자의 목록이며, SEC에 공개된 제출 문서에서 자동으로 생성됩니다. "이름", "가장 최근의 직급", "이사, 임원 또는 10% 주주"에 대한 지정 외에도 최근에 공개된 보유 주식에 대한 정보를 보여줍니다. 또한 가능한 경우 내부자의 과거 거래 실적도 확인 가능합니다. 과거 거래 실적은 내부자가 실제 "공개 시장"(Open market) 매입 거래를 수행한 실적을 가중 평균한 값입니다. 이 계산 방법에 대한 자세한 내용은 유튜브 웨비나 를 참조하시면 됩니다.

See our leaderboard of most profitable insider traders.

내부자	소유 지분	주식 분할
Kathleen Borthwick CFO - [O]	5,402	5,402
Cale Edgar B. GC & Corporate Secretary - [O]	45,995	2,300
William Chou PRESIDENT AND CEO, Director - [D] [O]	6,524	6,524
Athena Countouriotis Director - [D]	18,900	945
Fhmls Ix, L.l.c. 10% Owner - [10%]	5,009,219	250,461
Fhmls Ix, L.p. 10% Owner - [10%]	5,009,219	250,461
Mark S Forman CHIEF MEDICAL OFFICER - [O]	48,631	2,432
Alexandros Fotopoulos Chief Technical Officer - [O]	28,693	1,435
Frazier Life Sciences IX, L.P. 10% Owner - [10%]	5,009,219	250,461
Bruce A Goldsmith CEO and President, Director - [D] [O]	15,983	799
Patrick J Heron Director, 10% Owner - [D] [10%]	5,009,219	250,461

내부자	소유 지분	주식 분할
Saqib Islam Director - [D]	5,000	250
Sandip Kapadia Director - [D]	0	0
Simona King Chief Financial Officer - [O]	23,994	1,200
Lynx1 Capital Management LP 10% Owner - [10%]	623,704	623,704
Richard Steven Morris Chief Financial Officer - [O]	5,454	273
Orbimed Advisors Llc 10% Owner - [10%]	6,066,343	303,317
OrbiMed Capital GP VII LLC 10% Owner - [10%]	6,841,423	303,317
Quigley Jill M. Chief Operating Officer - [O]	368,754	18,438
Liam Ratcliffe Director - [D]	2,800	140
Gary Romano Chief Medical Officer - [O]	0	0
Stephen P Squinto Head of Research and Dev, Director - [D] [O]	1,337,150	66,858

내부자	소유 지분	주식 분할
Eliseo Oreste Salinas	157,500
Monika Maria Toernsen Chief Commercial Officer - [O]	3,319	166
James N Topper 10% Owner - [10%]	5,009,219	250,461
Versant Vantage I GP, L.P. 10% Owner - [10%]	933,352	46,668
Versant Vantage I GP-GP, LLC 10% Owner - [10%]	933,352	46,668
Versant Vantage I, L.P. 10% Owner - [10%]	933,352	46,668
Versant Venture Capital VI, L.P. 10% Owner - [10%]	933,352	46,668
Versant Ventures VI GP, L.P. 10% Owner - [10%]	933,352	46,668
Versant Ventures VI GP-GP, LLC 10% Owner - [10%]	933,352	46,668
Thomas Woiwode Director - [D]	933,352	46,668
Tadataka Yamada Director - [D]	656,149	32,807

Report errors via our new Insider Auditing Tool

내부자의 매입 내역 추적: 단기 이익 분석

이 섹션에서는 PASG / Passage Bio, Inc.에서 계획되지 않은 "공개 시장"(Open market)의 내부자가 매입한 모든 상품의 수익성을 분석합니다. 이 분석을 통해서 내부자가 비정상적인 수익을 지속적으로 창출하는지 파악하는 데 도움이 되며, 이러한 분석은 수행해볼 가치가 있습니다. 이 분석은 개별 거래 후 1년 동안 수행한 것이며, 결과는 이론 값입니다. .

아래 표는 사전 거래 계획(Automated trading plan)에 포함되지 않은 가장 최근의 "공개 시장"(Open market)에서의 매입을 보여줍니다.

거래일	내부자	보고된 지분	보고된 가격	조정된 지분	조정된 가격	가격 기준	최고까지 일수	최고에서 가격	최고 이익 ($)	최고 수익률 (%)
2025-09-15	Lynx1 Capital Management LP	11,900	6.9895	11,900	6.9895	83,175	116	19.8500	153,040	184.00
2025-09-12	Lynx1 Capital Management LP	19,783	6.9908	19,783	6.9908	138,299
2025-09-11	Lynx1 Capital Management LP	325	6.9558	325	6.9558	2,261
2025-07-24	Lynx1 Capital Management LP	66,423	5.7127	66,423	5.7127	379,455
2025-07-23	Lynx1 Capital Management LP	49,302	5.7408	49,302	5.7408	283,033
2025-07-22	Lynx1 Capital Management LP	13,123	5.4361	13,123	5.4361	71,338
2024-12-27	Lynx1 Capital Management LP	373,645	0.6451	18,682	12.9020	241,038
2024-11-27	Lynx1 Capital Management LP	29,300	0.6711	1,465	13.4220	19,663
2024-11-26	Lynx1 Capital Management LP	167,055	0.7075	8,353	14.1500	118,191

조정된 가격은 분할 조정 가격입니다. 조정된 지분은 분할 조정 지분입니다.

내부자 매매의 실적: 단기 손실 분석

이 섹선에서는 PASG / Passage Bio, Inc.에서 이루어진 "공개 시장(Open market)"에서의 모든 계획되지 않은 내부자 매매의 단기 손실 회피(Short-term loss avoidance)를 분석합니다. 일관된 손실 회피 패턴을 통해서 향후 매매 거래가 가격 하락을 초래할 수도 있음을 예상할 수 있습니다. 이 분석은 각 각 매매 거래 후 1년 동안의 자료이며, 결과는 이론 값입니다. .

아래 표는 사전 거래 계획(Automated trading plan)에 포함되지 않은 가장 최근의 공개 시장에서의 매매를 보여줍니다.

거래일	내부자	보고된 지분	보고된 가격	조정된 지분	조정된 가격	가격 기준	최저까지 일수	최저에서 가격	회피된 최대 손실($)	회피된 최대 손실율(%)
2026-01-08	Borthwick Kathleen	2,062	18.4394	2,062	18.4394	38,022	119	4.0800	-29,609	-77.87
2026-01-08	Chou William	4,076	18.4394	4,076	18.4394	75,159
2025-06-26	ORBIMED ADVISORS LLC	213,257	0.3300	10,663	6.6000	70,375
2025-06-25	ORBIMED ADVISORS LLC	138,800	0.3300	6,940	6.6000	45,804
2025-06-24	ORBIMED ADVISORS LLC	231,600	0.3500	11,580	7.0000	81,060
2025-04-24	ORBIMED ADVISORS LLC	68,195	0.3200	3,410	6.4000	21,822
2025-04-23	ORBIMED ADVISORS LLC	89,328	0.3400	4,466	6.8000	30,372
2025-04-22	ORBIMED ADVISORS LLC	78,049	0.3400	3,902	6.8000	26,537
2025-04-17	ORBIMED ADVISORS LLC	77,090	0.3300	3,854	6.6000	25,440

조정된 가격은 분할 조정 가격입니다. 조정된 지분은 분할 조정 지분입니다.

거래 내역

전체 거래 내역을 보려면 링크 아이콘을 클릭하세요. 10b5-1 자동 거래 계획의 일부로 보고된 거래는 10b-5 열에 X 표시가 나타납니다.

보고일	거래일	양식	내부자	티커	증권 소유권	코드	직접	행사 가격	단위 가격	단위 변동	가치 변동 (단위: 1,000)	잔여 옵션	잔여 주식
2026-01-12	2026-01-08	4	Chou William	PASG	Common Stock	S - Sale	D		18.4394	-4,076	-75		6,524
2026-01-12	2026-01-08	4	Chou William	PASG	Common Stock	M - Exercise	D			10,000			10,600
2026-01-12	2026-01-08	4	Borthwick Kathleen	PASG	Common Stock	S - Sale	D		18.4394	-2,062	-38		5,402
2026-01-12	2026-01-08	4	Borthwick Kathleen	PASG	Common Stock	M - Exercise	D			5,000			7,464
2025-09-15	2025-09-15	4	Lynx1 Capital Management LP	PASG	Common Stock	P - Purchase	I		6.9895	11,900	83		623,704
2025-09-15	2025-09-12	4	Lynx1 Capital Management LP	PASG	Common Stock	P - Purchase	I		6.9908	19,783	138		611,804
2025-09-15	2025-09-11	4	Lynx1 Capital Management LP	PASG	Common stock, $0.0001 par value per share (Common Stock)	P - Purchase	I		6.9558	325	2		592,021
2025-07-24	2025-07-24	4	Lynx1 Capital Management LP	PASG	Common Stock	P - Purchase	I		5.7127	66,423	379		591,696
2025-07-24	2025-07-23	4	Lynx1 Capital Management LP	PASG	Common Stock	P - Purchase	I		5.7408	49,302	283		525,273
2025-07-24	2025-07-22	4	Lynx1 Capital Management LP	PASG	Common stock, $0.0001 par value per share ("Common Stock")	P - Purchase	I		5.4361	13,123	71		475,971
2025-06-26	2025-06-26	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.3300	-213,257	-70		6,066,343
2025-06-26	2025-06-25	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.3300	-138,800	-46		6,279,600
2025-06-26	2025-06-24	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.3500	-231,600	-81		6,418,400
2025-04-24	2025-04-24	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.3200	-68,195	-22		6,650,000
2025-04-24	2025-04-23	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.3400	-89,328	-30		6,718,195
2025-04-24	2025-04-22	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.3400	-78,049	-27		6,807,523
2025-04-17	2025-04-17	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.3300	-77,090	-25		6,885,572
2025-04-17	2025-04-16	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.3300	-61,638	-20		6,962,662
2025-04-17	2025-04-15	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.3800	-10,326	-4		7,024,300
2025-02-12	2025-02-11	4	Borthwick Kathleen	PASG	Common Stock	S - Sale	D		0.5296	-3,183	-2		41,283
2025-02-12	2025-02-10	4	Borthwick Kathleen	PASG	Common Stock	M - Exercise	D			8,000			44,466
2025-01-14	2025-01-14	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.6000	-79,024	-47		7,034,626
2025-01-14	2025-01-13	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.6400	-17,986	-12		7,113,650
2025-01-14	2025-01-10	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.6600	-126,209	-83		7,131,636
2025-01-08	2025-01-08	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.6800	-75,007	-51		7,257,845
2025-01-08	2025-01-07	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.7100	-52,536	-37		7,332,852
2025-01-08	2025-01-06	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.7700	-19,481	-15		7,385,388
2024-12-31	2024-12-27	4	Lynx1 Capital Management LP	PASG	Common stock, $0.0001 par value per share	P - Purchase	I		0.6451	373,645	241		9,256,953
2024-12-26	2024-12-20	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.6000	-230,321	-138		7,404,869
2024-12-11	2024-12-11	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.8000	-80	-0		7,635,190
2024-12-11	2024-12-10	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.8000	-8,015	-6		7,635,270
2024-12-11	2024-12-09	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.8400	-54,181	-46		7,643,285
2024-12-06	2024-12-06	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.8200	-20,903	-17		7,697,466
2024-12-06	2024-12-04	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.7900	-76,200	-60		7,718,369
2024-11-27	2024-11-27	4	Lynx1 Capital Management LP	PASG	Common Stock	P - Purchase	I		0.6711	29,300	20		8,883,308
2024-11-27	2024-11-26	4	Lynx1 Capital Management LP	PASG	Common Stock	P - Purchase	I		0.7075	167,055	118		8,854,008
2024-11-27	2024-11-25	4	Lynx1 Capital Management LP	PASG	Common stock, $0.0001 par value per share ("Common Stock")	P - Purchase	I		0.5641	259,998	147		8,686,953
2024-09-23	2024-09-19	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.7100	-39,300	-28		7,794,569
2024-09-18	2024-09-18	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.7300	-25,631	-19		7,833,869
2024-09-18	2024-09-17	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.7300	-111,400	-81		7,859,500
2024-09-18	2024-09-16	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	S - Sale	I		0.7400	-63,100	-47		7,970,900
2024-08-09		3	Lynx1 Capital Management LP	PASG	Common stock, $0.0001 par value per share		I						8,426,955
2024-02-13	2024-02-13	4	Borthwick Kathleen	PASG	Common Stock	S - Sale	D		0.9700	-1,470	-1		28,466
2024-02-13	2024-02-10	4	Borthwick Kathleen	PASG	Common Stock	M - Exercise	D			4,000			29,936
2024-02-13	2024-02-13	4	Forman Mark S	PASG	Common Stock	S - Sale	D		0.9700	-1,638	-2		48,631
2024-02-13	2024-02-10	4	Forman Mark S	PASG	Common Stock	M - Exercise	D			5,000			50,269
2024-01-03	2024-01-02	4	Forman Mark S	PASG	Common Stock	S - Sale	D		0.9100	-15,813	-14		45,269
2024-01-03	2023-12-31	4	Forman Mark S	PASG	Common Stock	M - Exercise	D			50,000			61,082
2024-01-03	2024-01-02	4	Cale Edgar B.	PASG	Common Stock	S - Sale	D		0.9100	-15,813	-14		45,995
2024-01-03	2023-12-31	4	Cale Edgar B.	PASG	Common Stock	M - Exercise	D			50,000			61,808
2024-01-03	2024-01-02	4	Borthwick Kathleen	PASG	Common Stock	S - Sale	D		0.9100	-10,672	-10		25,936
2024-01-03	2023-12-31	4	Borthwick Kathleen	PASG	Common Stock	M - Exercise	D			30,000			36,608
2023-08-01	2023-07-28	4	King Simona	PASG	Common Stock	S - Sale	D		0.8800	-11,453	-10		23,994
2023-08-01	2023-07-28	4	King Simona	PASG	Common Stock	M - Exercise	D			31,250			35,447
2023-06-29	2023-06-28	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	P - Purchase	I		0.8400	575,195	483		8,034,000
2023-06-29	2023-06-27	4	ORBIMED ADVISORS LLC See footnotes	PASG	Common Stock	P - Purchase	I		0.8400	617,382	519		7,458,805
2023-06-20	2023-06-16	4	Fotopoulos Alexandros	PASG	Common Stock	S - Sale	D		0.9325	-4,052	-4		28,693
2023-06-20	2023-06-15	4	Fotopoulos Alexandros	PASG	Common Stock	M - Exercise	D			12,500			32,745
2023-04-20	2023-04-18	4	King Simona	PASG	Common Stock	S - Sale	D		1.0500	-2,053	-2		2,053
2023-04-20	2023-04-18	4	King Simona	PASG	Common Stock	M - Exercise	D			6,250			6,250
2022-12-02	2022-12-01	4	Kapadia Sandip	PASG	Common Stock	S - Sale	D		1.1929	-5,000	-6		0
2022-11-25	2022-11-22	4	Fotopoulos Alexandros	PASG	Common Stock	S - Sale	D		1.3300	-3,720	-5		20,245
2022-11-25	2022-11-22	4	Fotopoulos Alexandros	PASG	Common Stock	M - Exercise	D			12,500			23,965
2022-11-18	2022-09-19	4	Toernsen Monika Maria	PASG	Common Stock	S - Sale	D		1.5105	-1,681	-3		3,319
2022-11-18	2022-09-15	4	Toernsen Monika Maria	PASG	Common Stock	M - Exercise	D			5,000			5,000
2022-05-31	2022-05-26	4	Woiwode Thomas	PASG	Director Stock Option (Right to Buy)	A - Award	D	1.76		24,000		24,000
2022-05-31	2022-05-26	4	Porter Derrell	PASG	Director Stock Option (Right to Buy)	A - Award	D	1.76		24,000		24,000
2022-05-31	2022-05-26	4	Kapadia Sandip	PASG	Director Stock Option (Right to Buy)	A - Award	D	1.76		24,000		24,000
2022-05-31	2022-05-26	4	Islam Saqib	PASG	Director Stock Option (Right to Buy)	A - Award	D	1.76		24,000		24,000
2022-05-31	2022-05-26	4	GOWEN MAXINE	PASG	Director Stock Option (Right to Buy)	A - Award	D	1.76		24,000		24,000
2022-05-31	2022-05-26	4	Countouriotis Athena	PASG	Director Stock Option (Right to Buy)	A - Award	D	1.76		24,000		24,000
2022-05-05	2022-05-04	4	ORBIMED ADVISORS LLC See Footnotes	PASG	Common Stock	P - Purchase	I		1.9400	303,500	589		6,841,423
2022-05-05	2022-05-03	4	ORBIMED ADVISORS LLC See Footnotes	PASG	Common Stock	P - Purchase	I		1.9300	221,500	427		6,537,923
2022-05-05	2022-01-20	4/A	ORBIMED ADVISORS LLC See Footnotes	PASG	Common Stock	P - Purchase	I		5.0000	50,800	254		6,316,423
2022-04-20	2022-04-18	4	Forman Mark S	PASG	Employee Stock Options (right to buy)	A - Award	D	2.61		136,000		136,000
2022-04-20	2022-04-18	4	King Simona	PASG	Restricted Stock Unit	A - Award	D			25,000		25,000
2022-03-23	2022-03-21	4	Goldsmith Bruce A	PASG	Common Stock	P - Purchase	D		3.1500	10,000	32		15,983
2022-02-14	2022-02-10	4	Fotopoulos Alexandros	PASG	Stock Option (right to buy)	A - Award	D	4.52		163,900		163,900
2022-02-14	2022-02-10	4	Toernsen Monika Maria	PASG	Stock Option (right to buy)	A - Award	D	4.52		101,000		101,000
2022-02-14	2022-02-10	4	Salinas Eliseo Oreste	PASG	Stock Option (right to buy)	A - Award	D	4.52		157,500		157,500
2022-02-14	2022-02-10	4	King Simona	PASG	Stock Option (right to buy)	A - Award	D	4.52		159,000		159,000
2022-02-14	2022-02-10	4	Goldsmith Bruce A	PASG	Stock Option (right to buy)	A - Award	D	4.52		400,000		400,000
2022-02-14	2022-02-10	4	Cale Edgar B.	PASG	Stock Option (right to buy)	A - Award	D	4.52		106,000		106,000
2022-01-24	2022-01-20	4	ORBIMED ADVISORS LLC See Footnotes	PASG	Common Stock	P - Purchase	I		5.4200	369,100	2,001		6,634,723
2022-01-20	2022-01-19	4	ORBIMED ADVISORS LLC See Footnotes	PASG	Common Stock	P - Purchase	I		5.1100	43,300	221		6,265,623
2022-01-20	2022-01-18	4	ORBIMED ADVISORS LLC See Footnotes	PASG	Common Stock	P - Purchase	I		5.4600	114,700	626		6,222,323
2022-01-20	2022-01-14	4	ORBIMED ADVISORS LLC See Footnotes	PASG	Common Stock	P - Purchase	I		5.6000	10,300	58		6,107,623
2022-01-13	2022-01-13	4	ORBIMED ADVISORS LLC See Footnotes	PASG	Common Stock	P - Purchase	I		5.5200	41,800	231		6,097,323
2022-01-13	2022-01-12	4	ORBIMED ADVISORS LLC See Footnotes	PASG	Common Stock	P - Purchase	I		5.6500	100,000	565		6,055,523
2022-01-13	2022-01-11	4	ORBIMED ADVISORS LLC See Footnotes	PASG	Common Stock	P - Purchase	I		5.5300	8,200	45		5,955,523
2021-12-10	2021-12-08	4	Quigley Jill M.	PASG	Employee Stock Option (right to buy)	M - Exercise	D	0.23		-60,782		27,626
2021-12-10	2021-12-08	4	Quigley Jill M.	PASG	Employee Stock Option (right to buy)	M - Exercise	D	0.23		-11,193		3,729
2021-12-10	2021-12-08	4	Quigley Jill M.	PASG	Common Stock	M - Exercise	D		0.2300	71,975	17		368,754
2021-08-25	2021-08-23	4	King Simona	PASG	Employee Stock Option (Right to Buy)	A - Award	D	11.43		360,000		360,000
2021-07-21	2021-07-19	4	Toernsen Monika Maria	PASG	Restricted Stock Units	A - Award	D			20,000		20,000
2021-07-21	2021-07-19	4	Toernsen Monika Maria	PASG	Employee Stock Option (Right to Buy)	A - Award	D	13.04		200,000		200,000
2021-06-01	2021-05-27	4	GOWEN MAXINE	PASG	Director Stock Option (Right to Buy)	A - Award	D	13.83		4,542		4,542
2021-05-28	2021-05-27	4	Woiwode Thomas	PASG	Director Stock Option (Right to Buy)	A - Award	D	13.83		16,918		16,918
2021-05-28	2021-05-27	4	Yamada Tadataka	PASG	Director Stock Option (Right to Buy)	A - Award	D	13.83		16,918		16,918
2021-05-28	2021-05-27	4	Islam Saqib	PASG	Director Stock Option (Right to Buy)	A - Award	D	13.83		16,918		16,918
2021-05-28	2021-05-27	4	Kapadia Sandip	PASG	Director Stock Option (Right to Buy)	A - Award	D	13.83		16,918		16,918
2021-05-28	2021-05-27	4	Ratcliffe Liam	PASG	Director Stock Option (Right to Buy)	A - Award	D	13.83		16,918		16,918
2021-05-28	2021-05-27	4	Porter Derrell	PASG	Director Stock Option (Right to Buy)	A - Award	D	13.83		33,836		33,836
2021-05-28	2021-05-27	4	Countouriotis Athena	PASG	Director Stock Option (Right to Buy)	A - Award	D	13.83		16,918		16,918
2021-05-21	2021-05-21	4	Morris Richard Steven	PASG	Common Stock	P - Purchase	D		13.8183	2,171	30		5,454
2021-05-21	2021-05-21	4	Goldsmith Bruce A	PASG	Common Stock	P - Purchase	D		13.1150	2,000	26		5,983
2021-05-19	2021-05-17	4	Fotopoulos Alexandros	PASG	Restricted Stock Unit (RSU)	A - Award	D			50,000		50,000
2021-03-29	2021-03-22	4	Salinas Eliseo Oreste	PASG	Restricted Stock Unit (RSU)	A - Award	D			60,000		60,000
2021-03-29	2021-03-22	4	Salinas Eliseo Oreste	PASG	Restricted Stock Unit (RSU)	A - Award	D			40,000		40,000
2021-03-29	2021-03-22	4	Salinas Eliseo Oreste	PASG	Employee Stock Option (Right to buy)	A - Award	D	18.85		275,000		275,000
2021-03-17	2021-03-15	4	Romano Gary	PASG	Employee Stock Option (right to buy)	M - Exercise	D	8.07		-10,000		300,821
2021-03-17	2021-03-15	4	Romano Gary	PASG	Common Stock	S - Sale	D		21.8616	-1,617	-35		0
2021-03-17	2021-03-15	4	Romano Gary	PASG	Common Stock	S - Sale	D		20.9546	-8,383	-176		1,617
2021-03-17	2021-03-15	4	Romano Gary	PASG	Common Stock	M - Exercise	D		8.0700	10,000	81		10,000
2021-02-22	2021-02-18	4	GOWEN MAXINE	PASG	Stock Option (right to buy)	A - Award	D	21.46		33,836		33,836
2021-02-18	2021-02-16	4	Quigley Jill M.	PASG	Stock Option (right to buy)	A - Award	D	21.85		105,000		105,000
2021-02-18	2021-02-16	4	Morris Richard Steven	PASG	Stock Option (right to buy)	A - Award	D	21.85		50,000		50,000
2021-02-18	2021-02-16	4	Romano Gary	PASG	Stock Option (right to buy)	A - Award	D	21.85		105,000		105,000
2021-02-18	2021-02-16	4	Cale Edgar B.	PASG	Stock Option (right to buy)	A - Award	D	21.85		170,997		170,997
2021-02-18	2021-02-16	4	Goldsmith Bruce A	PASG	Stock Option (right to buy)	A - Award	D	21.85		262,000		262,000
2021-02-18	2021-02-16	4	Fotopoulos Alexandros	PASG	Stock Option (right to buy)	A - Award	D	21.85		105,000		105,000
2021-01-22	2021-01-20	4	Quigley Jill M.	PASG	Common Stock	S - Sale	D		30.0085	-1,300	-39		295,284
2021-01-15	2021-01-14	4	Quigley Jill M.	PASG	Common Stock	S - Sale	D		30.1000	16,298	491		296,584
2020-03-25	2020-03-24	4	Countouriotis Athena	PASG	Common Stock	P - Purchase	D		14.9750	10,000	150		18,900
2020-03-13	2020-03-03	4/A	Ratcliffe Liam By AI Passage LLC	PASG	Series B Preferred Stock	C - Conversion	I			-2,066,630		0
2020-03-13	2020-03-03	4/A	Ratcliffe Liam	PASG	Common Stock	P - Purchase	D		18.0000	2,800	50		2,800
2020-03-13	2020-03-03	4/A	Ratcliffe Liam By AI Passage LLC	PASG	Common Stock	P - Purchase	I		18.0000	550,000	9,900		2,616,630
2020-03-13	2020-03-03	4/A	Ratcliffe Liam By AI Passage LLC	PASG	Common Stock	C - Conversion	I			2,066,630			2,066,630
2020-03-03	2020-03-03	4	Versant Venture Capital VI, L.P. By Versant Vantage I, L.P.	PASG	Series B Preferred Stock	C - Conversion	I			-708,352		0
2020-03-03	2020-03-03	4	Versant Venture Capital VI, L.P.	PASG	Series A-2 Preferred Stock	C - Conversion	D			-1,049,175		0
2020-03-03	2020-03-03	4	Versant Venture Capital VI, L.P.	PASG	Series A-1 Preferred Stock	C - Conversion	D			-2,977,242		0
2020-03-03	2020-03-03	4	Versant Venture Capital VI, L.P. By Versant Vantage I, L.P.	PASG	Common Stock	P - Purchase	I		18.0000	225,000	4,050		933,352
2020-03-03	2020-03-03	4	Versant Venture Capital VI, L.P. By Versant Vantage I, L.P.	PASG	Common Stock	C - Conversion	I			708,352			708,352
2020-03-03	2020-03-03	4	Versant Venture Capital VI, L.P.	PASG	Common Stock	C - Conversion	D			1,049,175			4,026,417
2020-03-03	2020-03-03	4	Versant Venture Capital VI, L.P.	PASG	Common Stock	C - Conversion	D			2,977,242			2,977,242
2020-03-03	2020-03-03	4	ORBIMED ADVISORS LLC	PASG	Series B Preferred Stock	C - Conversion	I			-541,002		0
2020-03-03	2020-03-03	4	ORBIMED ADVISORS LLC	PASG	Series A-2 Preferred Stock	C - Conversion	I			-1,311,469		0
2020-03-03	2020-03-03	4	ORBIMED ADVISORS LLC	PASG	Series A-1 Preferred Stock	C - Conversion	I			-3,721,552		0
2020-03-03	2020-03-03	4	ORBIMED ADVISORS LLC	PASG	Common Stock	C - Conversion	I			541,002			5,947,323
2020-03-03	2020-03-03	4	ORBIMED ADVISORS LLC	PASG	Common Stock	C - Conversion	I			1,311,469			5,406,321
2020-03-03	2020-03-03	4	ORBIMED ADVISORS LLC	PASG	Common Stock	C - Conversion	I			3,721,552			4,094,852
2020-03-03	2020-02-28	4	ORBIMED ADVISORS LLC	PASG	Common Stock	P - Purchase	I		18.0000	373,300	6,719		373,300
2020-03-03	2020-03-03	4	Frazier Life Sciences IX, L.P.	PASG	Series B Preferred Stock	C - Conversion	D			-432,802		0
2020-03-03	2020-03-03	4	Frazier Life Sciences IX, L.P.	PASG	Series A-2 Preferred Stock	C - Conversion	D			-1,049,175		0
2020-03-03	2020-03-03	4	Frazier Life Sciences IX, L.P.	PASG	Series A-1 Preferred Stock	C - Conversion	D			-2,977,242		0
2020-03-03	2020-03-03	4	Frazier Life Sciences IX, L.P.	PASG	Common Stock	P - Purchase	D		18.0000	550,000	9,900		5,009,219
2020-03-03	2020-03-03	4	Frazier Life Sciences IX, L.P.	PASG	Common Stock	C - Conversion	D			432,802			4,459,219
2020-03-03	2020-03-03	4	Frazier Life Sciences IX, L.P.	PASG	Common Stock	C - Conversion	D			1,049,175			4,026,417
2020-03-03	2020-03-03	4	Frazier Life Sciences IX, L.P.	PASG	Common Stock	C - Conversion	D			2,977,242			2,977,242
2020-03-03	2020-03-03	4	Heron Patrick J By Frazier Life Sciences IX, L.P.	PASG	Series B Preferred Stock	C - Conversion	I			-432,802		0
2020-03-03	2020-03-03	4	Heron Patrick J By Frazier Life Sciences IX, L.P.	PASG	Series A-2 Preferred Stock	C - Conversion	I			-1,049,175		0
2020-03-03	2020-03-03	4	Heron Patrick J By Frazier Life Sciences IX, L.P.	PASG	Series A-1 Preferred Stock	C - Conversion	I			-2,977,242		0
2020-03-03	2020-03-03	4	Heron Patrick J By Frazier Life Sciences IX, L.P.	PASG	Common Stock	P - Purchase	I		18.0000	550,000	9,900		5,009,219
2020-03-03	2020-03-03	4	Heron Patrick J By Frazier Life Sciences IX, L.P.	PASG	Common Stock	C - Conversion	I			432,802			4,459,219
2020-03-03	2020-03-03	4	Heron Patrick J By Frazier Life Sciences IX, L.P.	PASG	Common Stock	C - Conversion	I			1,049,175			4,026,417
2020-03-03	2020-03-03	4	Heron Patrick J By Frazier Life Sciences IX, L.P.	PASG	Common Stock	C - Conversion	I			2,977,242			2,977,242
2020-03-03	2020-03-03	4	Woiwode Thomas By Versant Vantage I, L.P.	PASG	Series B Preferred Stock	C - Conversion	I			-708,352		0
2020-03-03	2020-03-03	4	Woiwode Thomas By Versant Venture Capital VI, L.P.	PASG	Series A-2 Preferred Stock	C - Conversion	I			-1,049,175		0
2020-03-03	2020-03-03	4	Woiwode Thomas By Versant Venture Capital VI, L.P.	PASG	Series A-1 Preferred Stock	C - Conversion	I			-2,977,242		0
2020-03-03	2020-03-03	4	Woiwode Thomas By Versant Vantage I, L.P.	PASG	Common Stock	P - Purchase	I		18.0000	225,000	4,050		933,352
2020-03-03	2020-03-03	4	Woiwode Thomas By Versant Vantage I, L.P.	PASG	Common Stock	C - Conversion	I			708,352			708,352
2020-03-03	2020-03-03	4	Woiwode Thomas By Versant Venture Capital VI, L.P.	PASG	Common Stock	C - Conversion	I			1,049,175			4,026,417
2020-03-03	2020-03-03	4	Woiwode Thomas By Versant Venture Capital VI, L.P.	PASG	Common Stock	C - Conversion	I			2,977,242			2,977,242
2020-03-03	2020-03-03	4	Ratcliffe Liam	PASG	Common Stock	P - Purchase	D		18.0000	2,800	50		2,800
2020-03-03	2020-03-03	4	Yamada Tadataka	PASG	Common Stock	P - Purchase	D		18.0000	6,500	117		656,149
2020-03-03	2020-03-03	4	Kapadia Sandip	PASG	Common Stock	P - Purchase	D		18.0000	5,000	90		5,000
2020-03-03	2020-03-03	4	Morris Richard Steven	PASG	Common Stock	P - Purchase	D		18.0000	400	7		400
2020-03-03	2020-03-03	4	Quigley Jill M. By Spouse	PASG	Common Stock	P - Purchase	I		18.0000	1,000	18		1,000
2020-03-03	2020-03-03	4	Quigley Jill M.	PASG	Common Stock	P - Purchase	D		18.0000	1,500	27		311,494
2020-03-03	2020-03-03	4	Countouriotis Athena	PASG	Common Stock	P - Purchase	D		18.0000	8,900	160		8,900
2020-03-03	2020-03-03	4	Fotopoulos Alexandros	PASG	Common Stock	P - Purchase	D		18.0000	5,500	99		5,500
2020-03-03	2020-03-03	4	Goldsmith Bruce A	PASG	Common Stock	P - Purchase	D		18.0000	1,100	20		1,100
2020-03-03	2020-03-03	4	Islam Saqib	PASG	Common Stock	P - Purchase	D		18.0000	5,000	90		5,000
2020-03-03	2020-03-03	4	Cale Edgar B.	PASG	Common Stock	P - Purchase	D		18.0000	2,000	36		2,000
2020-03-02	2020-02-27	4	Countouriotis Athena	PASG	Director Stock Option (Right to Buy)	A - Award	D	18.00		33,836		33,836
2020-03-02	2020-02-27	4	Woiwode Thomas	PASG	Director Stock Option (Right to Buy)	A - Award	D	18.00		33,836		33,836
2020-03-02	2020-02-27	4	Yamada Tadataka	PASG	Director Stock Option (Right to Buy)	A - Award	D	18.00		33,836		33,836
2020-03-02	2020-02-27	4	Heron Patrick J	PASG	Director Stock Option (Right to Buy)	A - Award	D	18.00		33,836		33,836
2020-03-02	2020-02-27	4	Islam Saqib	PASG	Director Stock Option (Right to Buy)	A - Award	D	18.00		16,918		16,918
2020-03-02	2020-02-27	4	Kapadia Sandip	PASG	Director Stock Option (Right to Buy)	A - Award	D	18.00		16,918		16,918
2020-03-02	2020-02-27	4	Ratcliffe Liam	PASG	Director Stock Option (Right to Buy)	A - Award	D	18.00		33,836		33,836
2020-03-02	2020-02-27	4	Morris Richard Steven	PASG	Employee Stock Option (Right to Buy)	A - Award	D	18.00		74,311		74,311
2020-03-02	2020-02-27	4	Romano Gary	PASG	Employee Stock Option (Right to Buy)	A - Award	D	18.00		74,311		74,311
2020-03-02	2020-02-27	4	Fotopoulos Alexandros	PASG	Employee Stock Option (Right to Buy)	A - Award	D	18.00		74,311		74,311
2020-03-02	2020-02-27	4	Cale Edgar B.	PASG	Employee Stock Option (Right to Buy)	A - Award	D	18.00		99,731		99,731
2020-03-02	2020-02-27	4	SQUINTO STEPHEN P	PASG	Director Stock Option (Right to Buy)	A - Award	D	18.00		33,836		33,836
2020-03-02	2020-02-27	4	SQUINTO STEPHEN P	PASG	Employee Stock Option (Right to Buy)	A - Award	D	18.00		185,776		185,776
2020-03-02	2020-02-27	4	Quigley Jill M.	PASG	Employee Stock Option (Right to Buy)	A - Award	D	18.00		211,001		211,001
2020-02-27		3	Yamada Tadataka	PASG	Common Stock		D						1,299,298
2020-02-27		3	Yamada Tadataka	PASG	Common Stock		D						1,299,298
2020-02-27		3	Yamada Tadataka	PASG	Common Stock		D						1,299,298
2020-02-27		3	SQUINTO STEPHEN P	PASG	Common Stock		D						1,337,150
2020-02-27		3	SQUINTO STEPHEN P	PASG	Common Stock		D						1,337,150
2020-02-27		3	SQUINTO STEPHEN P	PASG	Common Stock		D						1,337,150
2020-02-27		3	Quigley Jill M.	PASG	Common Stock		D						619,988
2020-02-27		3	Quigley Jill M.	PASG	Common Stock		D						619,988
2020-02-27		3	Quigley Jill M.	PASG	Common Stock		D						619,988

공개 시장에서 또는 사적으로 비파생증권 또는 파생증권 매입

공개 시장에서 또는 사적으로 비파생증권 또는 파생증권 매각

자사로부터 유가증권(옵션 등)을 보조, 지급 또는 기타 취득

파생상품 전환

자사에게 유가증권을 매각 또는 양도

기업으로부터 인도 받은 유가증권의 일부를 사용한 행사 가격 또는 조세 채무의 지급

내부자에 의한 또는 내부자에게 증권 증여

지분스왑 및 유사 위험 회피거래

자사로부터 인도 받은 파생증권(옵션 등)의 행사 또는 전환

보고서 양식 4에 자진 신고된 거래

기타 (거래 내용을 설명하는 각주와 동반)

PASG / Passage Bio, Inc. - Insider Trading and Ownership Report - SEC Form 3, 4, 5